Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07632196Recruiting
Nerve Stimulation to Improve Bowel Control After Rectal Cancer Surgery
This trial tests whether a small electrical device placed on the skin behind your ankle can help improve bowel control after surgery to remove rectal cancer. Many patients experience changes in bowel function after this surgery, and this treatment may help restore normal continence.
Manresa, BarcelonaAges 18 years+ - NCT07634991RecruitingPhase 4
N-acetyl Cysteine for Diabetic Eye Disease
This study tests whether a supplement called N-acetyl cysteine can help slow or improve mild to moderate diabetic eye disease (diabetic retinopathy). The goal is to see if it's safe and effective for people with type 2 diabetes.
CairoAges 18–70 - NCT06440746RecruitingPhase 2/Phase 3
Testing olokizumab for progressive lung scarring diseases
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
BarnaulAges 18 years+ - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT06510283RecruitingPhase 2
Taitacept for refractory or recurrent autoimmune encephalitis
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06566586RecruitingPhase 2
Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07627815RecruitingPhase 2
Safety and Efficacy of PNMR for Long COVID
This study tests whether PNMR (a supplement product) can safely reduce symptoms of long COVID—the lingering fatigue, brain fog, and other problems that some people experience months after COVID infection. You'll take the study product, follow diet and exercise guidelines, and complete questionnaires and a walking test.
Brampton, OntarioAges 19 years+ - NCT07625280RecruitingPhase 3
Twice-nightly treatment for narcolepsy or idiopathic hypersomnia
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
Birmingham, AlabamaAges 18–75 - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Peoria, ArizonaAges 18 years+ - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT07627347Recruiting
Anlotinib and Bemocizumab for Early Esophageal Cancer
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT07627516Recruiting
Spinal cord stimulation for arm and leg weakness after stroke
This trial tests whether a spinal cord stimulation device—a small implant that sends gentle electrical signals to your spinal cord—can help improve arm and leg strength and movement in people who had a stroke at least 6 months ago and haven't fully recovered with regular therapy. The goal is to see if this treatment is safe and effective.
Hangzhou, ZhejiangAges 20–80 - NCT07626736Recruiting
AI Planning Tools for Lung Cancer Team Care
This trial tests whether artificial intelligence can help doctors plan better treatment for non-small cell lung cancer (NSCLC). A team of specialists will use AI tools alongside their usual approach to see if it improves care and safety.
Guangzhou, GuangdongAges 18 years+ - NCT07627178Recruiting
Comparing laser treatments for enlarged prostate
This study compares three different surgical laser techniques to treat benign prostate enlargement (BPH) that causes severe urinary symptoms and hasn't improved with medication. The goal is to find which method is safest and works best for large prostates.
Tanta, Gharbia GovernorateAges Any age - NCT06697886RecruitingPhase 3
Antiwei Granules for Common Cold
This trial tests Antiwei Granules for treating the common cold. It looks for adults aged 18 to 65 who started having cold symptoms within the past 48 hours and have a mild fever.
BeijingAges 18–65 - NCT06698484RecruitingPhase 2
CAR-T cell therapy for B-cell lymphoma that has returned or not responded
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Bandar Tun Razak, Kuala LumpurAges 13–75 - NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05042453Recruiting
Long-term follow-up of Splentis for uterine prolapse repair
This trial follows women who have symptoms of uterine prolapse and are getting surgery with a device called Splentis. The study looks at whether Splentis works over the long term and whether it has any important side effects.
ChemnitzAges 18 years+ - NCT04920565Recruiting
Hemoperfusion with Polymyxin B for septic shock after heart surgery
This trial studies a blood-filter treatment (hemoperfusion with Polymyxin B) to reduce harmful substances in the blood for people who develop septic shock after heart surgery. It may help by lowering inflammation and improving safety, but it also requires meeting specific signs of severe infection and blood/bleeding conditions.
MoscowAges 18–80 - NCT06211114RecruitingPhase 2
Immunotherapy and targeted drug for advanced collecting duct kidney cancer
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07617246RecruitingPhase 2
Preventing nausea from cancer treatment with new medications
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
Hangzhou, ZhejiangAges 18 years+ - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.